{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pradaxa%2C+dabigatran+etexilate&page=3",
    "query": {
      "intervention": "Pradaxa, dabigatran etexilate",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 93,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pradaxa%2C+dabigatran+etexilate&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pradaxa%2C+dabigatran+etexilate&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T14:39:37.260Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01976507",
      "title": "Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Atrial Flutter"
      ],
      "interventions": [
        {
          "name": "dabigatran etexilate mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 101,
      "start_date": "2013-10",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2017-09-12",
      "last_synced_at": "2026-10-09T14:39:37.260Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01976507"
    },
    {
      "nct_id": "NCT00808067",
      "title": "RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "dabigatran dose 1",
          "type": "DRUG"
        },
        {
          "name": "dabigatran dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5897,
      "start_date": "2008-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-06-09",
      "last_synced_at": "2026-10-09T14:39:37.260Z",
      "location_count": 216,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Lake Havasu City, Arizona + 185 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Lake Havasu City",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00808067"
    },
    {
      "nct_id": "NCT00329238",
      "title": "Secondary Prevention of Venous Thrombo Embolism (VTE).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Dabigatran",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2867,
      "start_date": "2006-05",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-05-19",
      "last_synced_at": "2026-10-09T14:39:37.260Z",
      "location_count": 18,
      "location_summary": "Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00329238"
    },
    {
      "nct_id": "NCT02744092",
      "title": "Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Venous Thromboembolism",
        "Deep Vein Thrombosis (DVT)",
        "Pulmonary Embolism (PE)",
        "Blood Clot"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Dalteparin",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Fondaparinux",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance Foundation Trials, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 811,
      "start_date": "2016-12-13",
      "completion_date": "2021-02-22",
      "has_results": true,
      "last_update_posted_date": "2023-10-03",
      "last_synced_at": "2026-10-09T14:39:37.260Z",
      "location_count": 151,
      "location_summary": "Chula Vista, California • Fremont, California • Fresno, California + 104 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02744092"
    },
    {
      "nct_id": "NCT02228798",
      "title": "Perioperative Anticoagulant Use for Surgery Evaluation Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "McMaster University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3135,
      "start_date": "2014-08-01",
      "completion_date": "2018-08-31",
      "has_results": false,
      "last_update_posted_date": "2019-06-28",
      "last_synced_at": "2026-10-09T14:39:37.260Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Evanston, Illinois • Detroit, Michigan",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02228798"
    },
    {
      "nct_id": "NCT02164864",
      "title": "Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Percutaneous Coronary Intervention"
      ],
      "interventions": [
        {
          "name": "Dabigatran Etexilate 110mg",
          "type": "DRUG"
        },
        {
          "name": "Warfarin 3mg",
          "type": "DRUG"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran Etexilate 150mg",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel or Ticagrelor",
          "type": "DRUG"
        },
        {
          "name": "Warfarin 5mg",
          "type": "DRUG"
        },
        {
          "name": "Warfarin 1mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2725,
      "start_date": "2014-07-22",
      "completion_date": "2017-06-05",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-10-09T14:39:37.260Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cottonwood",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02164864"
    },
    {
      "nct_id": "NCT03026556",
      "title": "The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Dabigatran vs. Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran vs. Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42534,
      "start_date": "2016-12-29",
      "completion_date": "2017-08-23",
      "has_results": true,
      "last_update_posted_date": "2019-06-03",
      "last_synced_at": "2026-10-09T14:39:37.260Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03026556"
    },
    {
      "nct_id": "NCT02687867",
      "title": "Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Dabigatran (Pradaxa)",
          "type": "DRUG"
        },
        {
          "name": "Vitamin K antagonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56039,
      "start_date": "2016-02-12",
      "completion_date": "2016-03-01",
      "has_results": false,
      "last_update_posted_date": "2017-04-05",
      "last_synced_at": "2026-10-09T14:39:37.260Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02687867"
    },
    {
      "nct_id": "NCT03807856",
      "title": "Treating Acute Pancreatitis With Dabigatran, a Pilot Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Pancreatitis"
      ],
      "interventions": [
        {
          "name": "Dabigatran Etexilate Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2,
      "start_date": "2019-06-24",
      "completion_date": "2020-07-23",
      "has_results": false,
      "last_update_posted_date": "2022-09-01",
      "last_synced_at": "2026-10-09T14:39:37.260Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03807856"
    },
    {
      "nct_id": "NCT03006341",
      "title": "Validation of Predictors of OAC Initiation Using EMR Data",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Dabigatran etexilate",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140187,
      "start_date": "2017-02-28",
      "completion_date": "2017-05-09",
      "has_results": true,
      "last_update_posted_date": "2019-03-22",
      "last_synced_at": "2026-10-09T14:39:37.260Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03006341"
    }
  ]
}